Skip to content
2000
Volume 24, Issue 1
  • ISSN: 1568-0096
  • E-ISSN: 1873-5576

Abstract

Aim: The study aimed to explore the effect of metabolism on lung cancer. Background: The tumor microenvironment is largely influenced by metabolism, tightly involved in tumor progression. Objective: We try to investigate the effect of tumor metabolism terms on non-small cell lung cancer (NSCLC) prognosis, drug and immunotherapy sensitivity, as well as its underlying mechanisms. Methods: All the data was obtained from The Cancer Genome Atlas and Gene Expression Omnibus databases. R software was used to perform all statistical analyses and plots. Results: This study conducted 21 metabolism statuses in NSCLC to identify their underlying roles. We found that alpha-linolenic acid metabolism, sphingolipid metabolism, glycerophospholipid metabolism, fatty acid degradation, linoleic acid metabolism, primary bile acid biosynthesis, and fatty acid metabolism were protective factors for NSCLC. Next, we constructed a prognosis model based on primary bile acid biosynthesis, glycerophospholipid, and sphingolipid metabolism. Results in the present study showed that our model could effectively predict patients' prognosis in both training and validation cohorts. A clinical correlation revealed that patients at high-risk exhibited more progressive clinical characteristics. Biological enrichment indicated that MYC targets, E2F targets, mTORC1 signaling, G2/M checkpoint, and epithelial-mesenchymal transition were activated in the high-risk group. Immune relation analysis showed that risk score positively correlated with Th2 cells, yet a negative correlation with CD56 bright NK, Th17, mast and CD8+ T cells. Moreover, our model was related to NSCLC patients' sensitivity to immunotherapy and chemotherapy. Ultimately, eight characteristic genes were identified to distinguish the patients' risk group in the real application. Conclusions: The model we developed is a useful tool to predict NSCLC patients' prognosis and is associated with the sensitivity of immunotherapy and chemotherapy. Meanwhile, our results can guide the following metabolism-related studies in NSCLC.

Loading

Article metrics loading...

/content/journals/ccdt/10.2174/1568009623666230503094327
2024-01-01
2025-10-12
Loading full text...

Full text loading...

/content/journals/ccdt/10.2174/1568009623666230503094327
Loading

  • Article Type:
    Research Article
Keyword(s): chemotherapy; immune; immunotherapy; Metabolism; non-small cell lung cancer; prognosis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test